以毒攻毒原理
它基于以毒攻毒的基本原理，表明：导致在健康人身上出现疾病症状的某种物质，将能治疗病人身上的相似症状。多个欧洲国家早已将这种做法纳入到医疗护理体制中，包括法国、德国、荷兰、意大利、瑞士和葡萄牙，这个市场也在不断增长，特别是在英国和美国。
顺势疗法药物越来越频繁地出现在大规模零售网点中，用于治疗各种慢性疾病（例如哮喘、过敏、皮炎、类风湿性关节炎、肠易激综合症和精神健康问题）以及轻伤（例如割伤、擦伤、劳损或扭伤）。典型成分包括稀释剂量的某种动物、蔬菜或矿源物质，因此它们被视为温和且环保的药物。
GEA 解决方案
从制造角度来说，GEA 提供各种制粒和制丸设备，各种粉末处理、混合与搅拌技术，以及灌装胶囊的粉末处理机械。我们为制药和保健品行业的客户提供用于处理口服固体制剂的工程设计服务、完整的加工厂和独立的机器。
从称重、配量和卸料设备，到挤出机和抛圆机，从流化床处理机和高剪切制粒机，到旋转压片机和包衣机，GEA 有技术、经验和专业知识来提供各种制粒和干燥解决方案，包括批量、连续和单罐系统。此外，对基于液体的应用，我们在过滤、分离和离心作用的知识也是首屈一指的。如有需要，我们还可以在工艺和产品开发方面提供帮助。
产品与技术
显示 4 个，共 14 个
Fluid Bed Processors
For more than 50 years, GEA has supplied fluid bed processors for blending, granulating, drying, pelletizing and coating for the pharmaceutical industry. This includes small capacity systems designed for R&D as well as industrial size plants for batch production of pharmaceutical compounds under cGMP conditions.
High Shear Granulators
Our High Shear Granulator plants and granulation process expertise is based on experience and R&D. With plants installed around the world and literally thousands of tests performed, we have established a solid base of expertise related to the needs of the pharmaceutical manufacturing industry.
Integrated Granulation Lines
Current good manufacturing practices increasingly require that product is fully contained during processing to protect both operators and the environment. Integrated process systems not only offer containment, but also provide improved productivity through automation, increased yield and efficient cleaning procedures.
Pellet Production Lines
The pelletizing process for the production of pharmaceutical pellets - including extrusion and spheronization, production of pellets by powder layering and liquid layering and pelletization via melt and wet granulation processes.
Downloads
GEA 洞察
Reality check for biotech
The new GEA Application and Technology Center (ATC) in Sarstedt, south of Hannover, is neither a showroom nor a substitute for a lab. It is a place for testing, data collection and early decisions. This is where it becomes clear whether a biological concept can become a robust industrial process. That step is bigger than it may seem.
